Read more on P-BCMA-ALLO1 “showing promise in multiple myeloma” as featured in GEN | View our supporting IMS data here

Data to be highlighted in a Distinguished Industry Oral Abstract presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Scientific Meeting SAN DIEGO , Oct. 24, 2024 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and